Does Wellmark cover Wegovy?

It depends on your benefits. Wellmark covers Wegovy for liver disease (MASH) only when your plan includes that benefit and the policy requirements are met.

How long does a Wegovy approval last with Wellmark?

Liver Disease (MASH) — Applies to Employer plans. Initial approval: 12 months. Renewal: every 12 months.

What does Wellmark require to renew Wegovy?

Liver Disease (MASH) — Applies to Employer plans. Member has achieved or maintained a positive clinical response (e.g., improvement in liver function such as reduction in ALT, reduction of liver fat content by imaging such as MRI-PDFF or FibroScan CAP). No re-verification of specialist prescribing or fibrosis confirmation methods required at continuation.

How current is this information?

The oldest review date among the policies on this page is June 3, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Wellmark coverage for Wegovy (Liver Disease (MASH))

Full requirements: Wegovy for Liver Disease (MASH) (1 plan type)

Applies to Employer plans.

Depends on your plan's benefit

Covered only for select plans with specific benefit language allowing coverage of drugs for weight loss management or weight-related comorbidities; drugs for weight loss management are a standard exclusion for most benefit plans

Qualification pathways

You can qualify through any one of these.

MASH Initial Approval

All of:

Member has a diagnosis of MASH with moderate to advanced liver fibrosis consistent with stages F2 to F3, confirmed by liver biopsy, FAST (FibroScan-AST), MAST (MRI-PDFF + MRE + AST), or MEFIB (MRE + FIB-4)
Requested medication is prescribed by or in consultation with a gastroenterologist, hepatologist, cardiometabolic specialist, or primary care physician in consultation with any of the listed specialists
Member does not have evidence of cirrhosis, hepatic decompensation, or hepatocellular carcinoma
Requested medication will be used in conjunction with healthy lifestyle modifications (e.g., dietary or caloric restriction, exercise, behavioral support, community-based program)

MASH Continuation

All of:

Member is requesting medication for continuation of therapy for MASH
Member has achieved or maintained a positive clinical response (e.g., improvement in liver function such as reduction in ALT, reduction of liver fat content by imaging such as MRI-PDFF or FibroScan CAP)
Member does not have evidence of cirrhosis, hepatic decompensation, or hepatocellular carcinoma
Requested medication will be used in conjunction with healthy lifestyle modifications

Documentation to bring

Chart notes or medical records documenting clinical findings supporting the diagnosis of MASH
Documentation of liver fibrosis staging F2-F3 confirmed by liver biopsy, FAST score, MAST score, or MEFIB score
Documentation that medication is prescribed by or in consultation with a gastroenterologist, hepatologist, cardiometabolic specialist, or PCP in consultation with listed specialists
Documentation that member does not have evidence of cirrhosis, hepatic decompensation, or hepatocellular carcinoma
Documentation of positive clinical response for continuation (e.g., reduction in ALT, reduction of liver fat by MRI-PDFF or FibroScan CAP)

Quantity limits

All strengths — 4 pens

Approval and renewal

Initial approval: 12 months
Renewal: every 12 months
Renewal: Member has achieved or maintained a positive clinical response (e.g., improvement in liver function such as reduction in ALT, reduction of liver fat content by imaging such as MRI-PDFF or FibroScan CAP). No re-verification of specialist prescribing or fibrosis confirmation methods required at continuation.

Not covered when

Cirrhosis
Hepatic decompensation
Hepatocellular carcinoma
Plans without specific benefit language allowing weight loss drug coverage

Policy note: MASH indication applies only to Wegovy (semaglutide injection), not Wegovy HD or Wegovy tablet (which are not listed under section VII). Fibrosis confirmation methods accepted: liver biopsy, FAST (FibroScan-AST), MAST (derived from MRI-PDFF + MRE + AST), and MEFIB (MRE combined with FIB-4 index). No lookback periods specified for confirmation tests. The T2DM exclusion that applies to weight loss and cv risk reduction indications does NOT apply to MASH. Quantity limit applies to injection formulation only; semaglutide tablet quantity limit is 30 tabs/30 days.

Policy effective May 19, 2026 · verified June 3, 2026 · source: Drugs For Weight Loss Management · View policy document (PDF)

Open on its own page →

If liver disease (mash) isn't covered on your plan

A prior authorization can't override a benefit exclusion. Ask Wellmark about a formulary exception.

Questions people ask

Does Wellmark cover Wegovy?: It depends on your benefits. Wellmark covers Wegovy for liver disease (MASH) only when your plan includes that benefit and the policy requirements are met.
How long does a Wegovy approval last with Wellmark?: Liver Disease (MASH) — Applies to Employer plans. Initial approval: 12 months. Renewal: every 12 months.
What does Wellmark require to renew Wegovy?: Liver Disease (MASH) — Applies to Employer plans. Member has achieved or maintained a positive clinical response (e.g., improvement in liver function such as reduction in ALT, reduction of liver fat content by imaging such as MRI-PDFF or FibroScan CAP). No re-verification of specialist prescribing or fibrosis confirmation methods required at continuation.
How current is this information?: The oldest review date among the policies on this page is June 3, 2026. Each policy's effective and verification dates appear with its requirements. Confirm current benefits with your plan.

Does Wellmark cover Wegovy for Liver Disease (MASH)?

Policy document